Details of the Drug

General Information of Drug (ID: DMLOQ1V)

Drug Name

Tasimelteon

Synonyms

Tasimelteon; 609799-22-6; Hetlioz; VEC-162; BMS-214778; VEC 162; UNII-SHS4PU80D9; BMS 214778; SHS4PU80D9; CHEBI:79042; N-{[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl}propanamide; Tasimelteon [USAN:INN]; tasimelteonum; N-([(1r,2r)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl)propanamide; N-[[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl]propanamide; N-(((1R,2R)-2-(2,3-Dihydro-1-benzofuran-4-yl)cyclopropyl)methyl)propanamide; Hetlioz (TN); Tasimelteon (USAN/INN); SCHEMBL3505912; GTPL7393

Indication

Disease Entry	ICD 11	Status	REF
Insomnia	7A00-7A0Z	Approved	[1], [2]

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

245.32

Topological Polar Surface Area (xlogp)

2.2

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Clearance: The drug present in the plasma can be removed from the body at the rate of 9.04 mL/min/kg [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 1.3 +/- 0.4 hours [3]
Metabolism: The drug is metabolized via the further oxidation to give a carboxylic acid [4]
Vd: The volume of distribution (Vd) of drug is 56-126 L [5]

Chemical Identifiers

Formula: C15H19NO2
IUPAC Name: N-[[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl]propanamide
Canonical SMILES: CCC(=O)NC[C@@H]1C[C@H]1C2=C3CCOC3=CC=C2
InChI: InChI=1S/C15H19NO2/c1-2-15(17)16-9-10-8-13(10)11-4-3-5-14-12(11)6-7-18-14/h3-5,10,13H,2,6-9H2,1H3,(H,16,17)/t10-,13+/m0/s1
InChIKey: PTOIAAWZLUQTIO-GXFFZTMASA-N

Cross-matching ID

PubChem CID: 10220503
ChEBI ID: CHEBI:79042
CAS Number: 609799-22-6
DrugBank ID: DB09071
TTD ID: D0Q5MQ
INTEDE ID: DR1532
ACDINA ID: D01461

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Melatonin receptor type 1A (MTNR1A)	TT0WAIE	MTR1A_HUMAN	Agonist	[1]
Melatonin receptor type 1B (MTNR1B)	TT32JK8	MTR1B_HUMAN	Agonist	[1]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[6]
Cytochrome P450 1A2 (CYP1A2)_{Main DME}	DEJGDUW	CP1A2_HUMAN	Substrate	[6]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Tasimelteon (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Moderate	Increased metabolism of Tasimelteon caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[42]
Arn-509	DMT81LZ	Major	Increased metabolism of Tasimelteon caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[42]
Oliceridine	DM6MDCF	Major	Additive CNS depression effects by the combination of Tasimelteon and Oliceridine.	Acute pain [MG31]	[43]
Pexidartinib	DMS2J0Z	Moderate	Increased metabolism of Tasimelteon caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[42]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Tasimelteon caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[42]
Osilodrostat	DMIJC9X	Moderate	Decreased metabolism of Tasimelteon caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[42]
Lumacaftor	DMCLWDJ	Major	Increased metabolism of Tasimelteon caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[44]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Tasimelteon caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[42]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Tasimelteon and Esketamine.	Depression [6A70-6A7Z]	[45]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Tasimelteon caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[42]
Eslicarbazepine	DMZREFQ	Moderate	Increased metabolism of Tasimelteon caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[42]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Tasimelteon caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[42]
Givosiran	DM5PFIJ	Moderate	Decreased metabolism of Tasimelteon caused by Givosiran mediated inhibition of CYP450 enzyme.	Inborn porphyrin/heme metabolism error [5C58]	[42]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Tasimelteon caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[42]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Tasimelteon caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[42]
Osimertinib	DMRJLAT	Moderate	Increased metabolism of Tasimelteon caused by Osimertinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[42]
Capmatinib	DMYCXKL	Moderate	Decreased metabolism of Tasimelteon caused by Capmatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[42]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Tasimelteon caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[42]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Tasimelteon caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[42]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Tasimelteon and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[46]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Tasimelteon and Lasmiditan.	Migraine [8A80]	[47]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Tasimelteon caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[42]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Tasimelteon caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[42]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Tasimelteon caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[48]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Tasimelteon caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[49]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Tasimelteon caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[42]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Tasimelteon caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[50]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Tasimelteon caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[45]
LEE011	DMMX75K	Moderate	Decreased metabolism of Tasimelteon caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[42]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Tasimelteon caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[51]
Elagolix	DMB2C0E	Moderate	Increased metabolism of Tasimelteon caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[42]
-----------


⏷ Show the Full List of 31 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Erythrosine sodium anhydrous	E00324	27872	Colorant
FD&C blue no. 1	E00263	19700	Colorant
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Sodium benzoate	E00432	517055	Antimicrobial preservative; lubricant
Sucralose	E00370	71485	Flavoring agent
Sunset yellow FCF	E00255	17730	Colorant
Ascorbic acid	E00579	54670067	Acidulant; Antioxidant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium	E00625	Not Available	Disintegrant
Gelatin	E00630	Not Available	Other agent
Magnesium stearate	E00208	11177	lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Sodium chloride	E00077	5234	Diluent; Tonicity agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Water	E00035	962	Solvent
Hydrophobic colloidal silica	E00285	24261	Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent
--------------------


⏷ Show the Full List of 18 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Tasimelteon 20mg capsule	20mg	Capsule	Oral
Tasimelteon 4mg/ml suspension	4mg/ml	Suspension	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7393).
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
5	An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
6	Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist. J Clin Pharmacol. 2015 Sep;55(9):1004-11.
7	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
8	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
9	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
10	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
11	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
12	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
13	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
14	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
15	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
16	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
17	Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
18	Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
19	Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
20	PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
21	The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
22	The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
23	Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
24	Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
25	MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential. J Med Chem. 2014 Apr 24;57(8):3161-85.
26	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
27	Synthesis of nitroindole derivatives with high affinity and selectivity for melatoninergic binding sites MT(3). J Med Chem. 2002 Apr 25;45(9):1853-9.
28	Mapping the melatonin receptor. 2. synthesis and biological activity of indole derived melatonin analogues with restricted conformations of the C-3 amidoethane side chain, Bioorg. Med. Chem. Lett. 4(13):1559-1564 (1994).
29	Design and synthesis of benzofuranic derivatives as new ligands at the melatonin-binding site MT3. Bioorg Med Chem. 2008 May 1;16(9):4954-62.
30	Synthesis of substituted N-[3-(3-methoxyphenyl)propyl] amides as highly potent MT(2)-selective melatonin ligands. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2582-5.
31	Mapping the melatonin receptor. 7. Subtype selective ligands based on beta-substituted N-acyl-5-methoxytryptamines and beta-substituted N-acyl-5-me... J Med Chem. 2006 Jun 15;49(12):3509-19.
32	2-[(2,3-dihydro-1H-indol-1-yl)methyl]melatonin analogues: a novel class of MT2-selective melatonin receptor antagonists. J Med Chem. 2009 Feb 12;52(3):826-33.
33	The human MT1 melatonin receptor stimulates cAMP production in the human neuroblastoma cell line SH-SY5Y cells via a calcium-calmodulin signal transduction pathway. J Neuroendocrinol. 2005 Mar;17(3):170-8.
34	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 288).
35	Melatonin and sleep in aging population. Exp Gerontol. 2005 Dec;40(12):911-25.
36	Melatonin receptor agonists: SAR and applications to the treatment of sleep-wake disorders. Curr Top Med Chem. 2008;8(11):954-68.
37	Luzindole (N-0774): a novel melatonin receptor antagonist. J Pharmacol Exp Ther. 1988 Sep;246(3):902-10.
38	Effects of two melatonin analogues, S-20098 and S-20928, on melatonin receptors in the pars tuberalis of the rat. J Pineal Res. 1998 Oct;25(3):172-6.
39	US patent application no. 5,151,446, Substituted 2-amidotetralins as melatonin agonists and antagonists.
40	Novel non-indolic melatonin receptor agonists differentially entrain endogenous melatonin rhythm and increase its amplitude. Eur J Pharmacol. 1999 Oct 15;382(3):157-66.
41	US patent application no. 2005,016,4987, Melatonin combination therapy for improving sleep quality.
42	Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
43	US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
44	Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John's Wort." Am J Med 112 (2002): 507-8. [PMID: 11959071]
45	Cerner Multum, Inc. "Australian Product Information.".
46	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
47	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
48	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
49	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
50	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
51	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.